NIAID Award For Needle-Free Dengue Vaccine

Oct. 18, 2010, 8:47 a.m.

The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a $15.5 million to two companies for the development of a needle-free dengue vaccine, using a technology that has been preliminarily tested on animals, in-PharmaTechnologist.com reports. The grant, awarded to Inviragen and PhramaJet to work in a five-year partnership, will cover "preclinical, regulatory filings, manufacturing and clinical testing of the needle-free dengue vaccine" (Taylor, 10/11). Denver Business Journal adds that needle-free technology, which delivers medicine through the skin, "removes hygienic and health concerns associated with the use and re-use of needles in poor countries" (Avery, 10/8). According to an Inviragen press release (.pdf), the needle-free technology will use the company's DENVax dengue vaccine, which is currently in Phase I testing for safety using the using the traditional needle and syringe (10/7).

 

http://globalhealth.kff.org/Daily-Reports/2010/October/12/GH-101210-Roundups.aspx

<< News Archive